| Identification | Back Directory | [Name]
RG7834 (Synonyms: RO 7020322) | [CAS]
2072057-17-9 | [Synonyms]
RG7834 (RO 7020322)
RG7834 (Synonyms: RO 7020322)
2H-Benzo[a]quinolizine-3-carboxylic acid, 6,7-dihydro-10-methoxy-9-(3-methoxypropoxy)-6-(1-methylethyl)-2-oxo-, (6S)- | [Molecular Formula]
C22H27NO6 | [MDL Number]
MFCD31555773 | [MOL File]
2072057-17-9.mol | [Molecular Weight]
401.45 |
| Chemical Properties | Back Directory | [Boiling point ]
578.6±50.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:100.0(Max Conc. mg/mL);249.1(Max Conc. mM) | [form ]
Solid | [pka]
5.91±0.40(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells[1]. | [in vivo]
RG7834 (4 mg/kg, twice daily for 21 days) shows anti-HBV efficacy in HBV-infected human liver chimeric uPA-SCID mice[1].
RG7834 (2, 14.5 mg/kg, p.o.) exhibits good oral bioavail ability, with a half-life of 4.9 h in mice[1]. | Animal Model: | HBV-infected human liver chimeric uPA-SCID mice[1] | | Dosage: | 4 mg/kg | | Administration: | Twice daily for 21 days | | Result: | Reduced both HBsAg and HBeAg, also decreased serum HBV DNA by 0.6 log10 in mice. |
| [storage]
Store at -20°C | [References]
[1] Han X, et al. Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action. J Med Chem. 2018 Oct 4. DOI:10.1021/acs.jmedchem.8b01245 |
|
|